BeiGene (BGNE) Tops Q4 EPS by 1c, Misses on Revenue

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. SPY
3. LLY
4. META
5. MSFT
6. SPCX
7. AZN
8. FLG
9. FICO
10. GMAB

Go back to BeiGene (BGNE) Tops Q4 EPS by 1c, Misses on Revenue

BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

February 26, 2024 6:00 AM EST

Continued rapid global growth with record total revenues of $634 million in fourth quarter and $2.5 billion in full-year 2023, increases of 67% and 74% from the prior-year periods Strengthened leadership in hematology with global BRUKINSA® (zanubrutinib) sales of $413 million and $1.3 billion for the quarter and full year, increases of 135% and 129% Progressed innovative hematology pipeline with initiation of four registrational trials for sonrotoclax, including global Phase 3 study in treatment-naïve CLL, and two global expansion cohorts for BTK CDAC in R/R CLL, R/R MCL Sustained growth with diverse product and geographic revenue mix and... More